EcoDrugPlus

Potassium Two Pore Domain Channel Subfamily K Member 9

Ensembl ID : ENSDNOG00000025183
Gene Symbol: KCNK9
2 Cross references
215 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily A Member 5

Ensembl ID : ENSDNOG00000012639
Gene Symbol: KCNA5
4 Cross references
170 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily H Member 2

Ensembl ID : ENSDNOG00000012134
Gene Symbol: KCNH2
2 Cross references
253 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSDNOG00000004984
Gene Symbol: KCNQ3
2 Cross references
193 Possible Orthologues:

Presenilin 1

Ensembl ID : ENSDNOG00000030820
Gene Symbol: PSEN1
4 Cross references
202 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSDNOG00000035429
Gene Symbol: PSENEN
4 Cross references
185 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSDNOG00000048850
Gene Symbol: PGR
2 Cross references
194 Possible Orthologues:

Prostaglandin D2 Receptor

Ensembl ID : ENSDNOG00000003560
Gene Symbol: PTGDR
4 Cross references
118 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSDNOG00000006257
Gene Symbol: PTGDR2
4 Cross references
205 Possible Orthologues:

Prostaglandin E Receptor 1

Ensembl ID : ENSDNOG00000041674
Gene Symbol: PTGER1
4 Cross references
237 Possible Orthologues:

Prostaglandin E Receptor 2

Ensembl ID : ENSDNOG00000041288
Gene Symbol: PTGER2
2 Cross references
244 Possible Orthologues:

Prostaglandin E Receptor 3

Ensembl ID : ENSDNOG00000010437
Gene Symbol: PTGER3
2 Cross references
196 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).